O	0	7	Mitogen	Mitogen	NN	B-NP
O	7	8	-	-	HYPH	B-PP
O	8	17	activated	activate	VBN	B-NP
O	18	25	protein	protein	NN	I-NP
O	26	32	kinase	kinase	NN	I-NP
O	33	39	kinase	kinase	NN	I-NP
O	40	49	signaling	signaling	NN	I-NP
O	50	58	promotes	promote	VBZ	B-VP
O	59	65	growth	growth	NN	B-NP
O	66	69	and	and	CC	I-NP
O	70	85	vascularization	vascularization	NN	I-NP
O	86	88	of	of	IN	B-PP
B-Cancer	89	101	fibrosarcoma	fibrosarcoma	NN	B-NP
O	101	102	.	.	.	O

O	103	105	We	We	PRP	B-NP
O	106	118	hypothesized	hypothesize	VBD	B-VP
O	119	123	that	that	IN	B-SBAR
O	124	133	signaling	signaling	NN	B-NP
O	134	141	through	through	IN	B-PP
O	142	150	multiple	multiple	JJ	B-NP
O	151	158	mitogen	mitogen	NN	I-NP
O	158	159	-	-	HYPH	B-VP
O	159	168	activated	activate	VBN	B-NP
O	169	176	protein	protein	NN	I-NP
O	177	183	kinase	kinase	NN	I-NP
O	184	185	(	(	(	O
O	185	189	MAPK	MAPK	NN	B-NP
O	189	190	)	)	)	O
O	191	197	kinase	kinase	NN	B-NP
O	198	199	(	(	(	O
O	199	202	MKK	MKK	NN	B-NP
O	202	203	)	)	)	O
O	204	212	pathways	pathway	NNS	B-NP
O	213	215	is	be	VBZ	B-VP
O	216	225	essential	essential	JJ	B-ADJP
O	226	229	for	for	IN	B-PP
O	230	233	the	the	DT	B-NP
O	234	240	growth	growth	NN	I-NP
O	241	244	and	and	CC	I-NP
O	245	260	vascularization	vascularization	NN	I-NP
O	261	263	of	of	IN	B-PP
B-Cancer	264	268	soft	soft	JJ	B-NP
I-Cancer	268	269	-	-	HYPH	I-NP
I-Cancer	269	275	tissue	tissue	NN	I-NP
I-Cancer	276	284	sarcomas	sarcoma	NNS	I-NP
O	284	285	,	,	,	O
O	286	291	which	which	WDT	B-NP
O	292	295	are	be	VBP	B-VP
B-Cancer	296	305	malignant	malignant	JJ	B-NP
I-Cancer	306	312	tumors	tumor	NNS	I-NP
O	313	320	derived	derive	VBN	B-VP
O	321	325	from	from	IN	B-PP
B-Tissue	326	337	mesenchymal	mesenchymal	JJ	B-NP
I-Tissue	338	345	tissues	tissue	NNS	I-NP
O	345	346	.	.	.	O

O	347	349	We	We	PRP	B-NP
O	350	356	tested	test	VBD	B-VP
O	357	361	this	this	DT	B-NP
O	362	367	using	use	VBG	I-NP
B-Cell	368	370	HT	HT	NN	I-NP
I-Cell	370	371	-	-	HYPH	B-NP
I-Cell	371	375	1080	1080	CD	I-NP
O	375	376	,	,	,	O
B-Cell	377	380	NCI	NCI	NN	B-NP
O	380	381	,	,	,	O
O	382	385	and	and	CC	O
B-Cell	386	390	Shac	Shac	NN	B-NP
I-Cell	391	403	fibrosarcoma	fibrosarcoma	NN	I-NP
I-Cell	403	404	-	-	HYPH	B-VP
I-Cell	404	411	derived	derive	VBN	B-NP
I-Cell	412	416	cell	cell	NN	I-NP
I-Cell	417	422	lines	line	NNS	I-NP
O	423	426	and	and	CC	O
O	427	434	anthrax	anthrax	NN	B-NP
O	435	441	lethal	lethal	JJ	I-NP
O	442	447	toxin	toxin	NN	I-NP
O	448	449	(	(	(	O
O	449	453	LeTx	LeTx	NN	B-NP
O	453	454	)	)	)	O
O	454	455	,	,	,	O
O	456	457	a	a	DT	B-NP
O	458	467	bacterial	bacterial	JJ	I-NP
O	468	473	toxin	toxin	NN	I-NP
O	474	478	that	that	WDT	B-NP
O	479	490	inactivates	inactivate	VBZ	B-VP
O	491	495	MKKs	MKK	NNS	B-NP
O	495	496	.	.	.	O

O	497	504	Western	Western	JJ	B-NP
O	505	510	blots	blot	NNS	I-NP
O	511	520	confirmed	confirm	VBD	B-VP
O	521	525	that	that	IN	B-SBAR
O	526	530	LeTx	LeTx	NN	B-NP
O	531	540	treatment	treatment	NN	I-NP
O	541	548	reduced	reduce	VBD	B-VP
O	549	552	the	the	DT	B-NP
O	553	559	levels	level	NNS	I-NP
O	560	562	of	of	IN	B-PP
O	563	577	phosphorylated	phosphorylate	VBN	B-NP
O	578	591	extracellular	extracellular	JJ	I-NP
O	592	598	signal	signal	NN	I-NP
O	598	599	-	-	HYPH	B-NP
O	599	608	regulated	regulate	VBN	I-NP
O	609	615	kinase	kinase	NN	I-NP
O	616	619	and	and	CC	I-NP
O	620	623	p38	p38	NN	I-NP
O	624	628	MAPK	MAPK	NN	I-NP
O	629	631	in	in	FW	B-ADVP
O	632	637	vitro	vitro	FW	I-ADVP
O	637	638	.	.	.	O

O	639	647	Although	Although	IN	B-SBAR
O	648	653	short	short	JJ	B-NP
O	654	664	treatments	treatment	NNS	I-NP
O	665	669	with	with	IN	B-PP
O	670	674	LeTx	LeTx	NN	B-NP
O	675	679	only	only	RB	B-ADVP
O	680	688	modestly	modestly	RB	B-VP
O	689	697	affected	affect	VBD	I-VP
B-Cell	698	702	cell	cell	NN	B-NP
O	703	716	proliferation	proliferation	NN	I-NP
O	716	717	,	,	,	O
O	718	727	sustained	sustain	VBD	B-VP
O	728	737	treatment	treatment	NN	B-NP
O	738	746	markedly	markedly	RB	B-ADVP
O	747	754	reduced	reduce	VBD	B-VP
B-Cell	755	759	cell	cell	NN	B-NP
O	760	767	numbers	number	NNS	I-NP
O	767	768	.	.	.	O

O	769	773	LeTx	LeTx	NN	B-NP
O	774	778	also	also	RB	B-ADVP
O	779	792	substantially	substantially	RB	B-VP
O	793	802	inhibited	inhibit	VBD	I-VP
O	803	806	the	the	DT	B-NP
B-Immaterial_anatomical_entity	807	820	extracellular	extracellular	JJ	I-NP
O	821	828	release	release	NN	I-NP
O	829	831	of	of	IN	B-PP
O	832	850	angioproliferative	angioproliferative	JJ	B-NP
O	851	858	factors	factor	NNS	I-NP
O	859	868	including	include	VBG	B-PP
O	869	877	vascular	vascular	JJ	B-NP
O	878	889	endothelial	endothelial	JJ	I-NP
O	890	896	growth	growth	NN	I-NP
O	897	903	factor	factor	NN	I-NP
O	903	904	,	,	,	O
O	905	916	interleukin	interleukin	NN	B-NP
O	916	917	-	-	HYPH	O
O	917	918	8	8	CD	B-NP
O	918	919	,	,	,	O
O	920	923	and	and	CC	O
O	924	929	basic	basic	JJ	B-NP
O	930	940	fibroblast	fibroblast	NN	I-NP
O	941	947	growth	growth	NN	I-NP
O	948	954	factor	factor	NN	I-NP
O	954	955	.	.	.	O

O	956	963	Similar	Similar	JJ	B-NP
O	964	971	results	result	NNS	I-NP
O	972	976	were	be	VBD	B-VP
O	977	985	obtained	obtain	VBN	I-VP
O	986	990	with	with	IN	B-PP
B-Cell	991	995	cell	cell	NN	B-NP
I-Cell	996	1001	lines	line	NNS	I-NP
O	1002	1009	derived	derive	VBN	B-VP
O	1010	1014	from	from	IN	B-PP
B-Cancer	1015	1024	malignant	malignant	JJ	B-NP
I-Cancer	1025	1032	fibrous	fibrous	JJ	I-NP
I-Cancer	1033	1046	histiocytomas	histiocytoma	NNS	I-NP
O	1046	1047	,	,	,	O
B-Cancer	1048	1063	leiomyosarcomas	leiomyosarcoma	NNS	B-NP
O	1063	1064	,	,	,	O
O	1065	1068	and	and	CC	O
B-Cancer	1069	1081	liposarcomas	liposarcoma	NNS	B-NP
O	1081	1082	.	.	.	O

O	1083	1085	In	In	FW	B-ADVP
O	1086	1090	vivo	vivo	FW	I-ADVP
O	1090	1091	,	,	,	O
O	1092	1096	LeTx	LeTx	NNP	B-NP
O	1097	1106	decreased	decrease	VBD	B-VP
O	1107	1111	MAPK	MAPK	NN	B-NP
O	1112	1120	activity	activity	NN	I-NP
O	1121	1124	and	and	CC	O
O	1125	1132	blocked	block	VBD	B-VP
B-Cancer	1133	1145	fibrosarcoma	fibrosarcoma	NN	B-NP
O	1146	1152	growth	growth	NN	I-NP
O	1152	1153	.	.	.	O

O	1154	1160	Growth	Growth	NN	B-NP
O	1161	1171	inhibition	inhibition	NN	I-NP
O	1172	1182	correlated	correlate	VBD	B-VP
O	1183	1187	with	with	IN	B-PP
O	1188	1197	decreased	decrease	VBN	B-NP
B-Cell	1198	1206	cellular	cellular	JJ	I-NP
O	1207	1220	proliferation	proliferation	NN	I-NP
O	1221	1224	and	and	CC	O
O	1225	1234	extensive	extensive	JJ	B-NP
O	1235	1243	necrosis	necrosis	NN	I-NP
O	1243	1244	,	,	,	O
O	1245	1248	and	and	CC	O
O	1249	1251	it	it	PRP	B-NP
O	1252	1255	was	be	VBD	B-VP
O	1256	1267	accompanied	accompany	VBN	I-VP
O	1268	1270	by	by	IN	B-PP
O	1271	1272	a	a	DT	B-NP
O	1273	1281	decrease	decrease	NN	I-NP
O	1282	1284	in	in	IN	B-PP
B-Cancer	1285	1290	tumor	tumor	NN	B-NP
O	1291	1295	mean	mean	JJ	I-NP
B-Multi-tissue_structure	1296	1302	vessel	vessel	NN	I-NP
O	1303	1310	density	density	NN	I-NP
O	1311	1313	as	as	RB	B-CONJP
O	1314	1318	well	well	RB	I-CONJP
O	1319	1321	as	as	IN	I-CONJP
O	1322	1323	a	a	DT	B-NP
O	1324	1333	reduction	reduction	NN	I-NP
O	1334	1336	in	in	IN	B-PP
B-Organism_substance	1337	1342	serum	serum	NN	B-NP
O	1343	1353	expression	expression	NN	I-NP
O	1354	1356	of	of	IN	B-PP
O	1357	1375	angioproliferative	angioproliferative	JJ	B-NP
O	1376	1385	cytokines	cytokine	NNS	I-NP
O	1385	1386	.	.	.	O

O	1387	1392	Vital	Vital	JJ	B-NP
O	1393	1400	imaging	imaging	NN	I-NP
O	1401	1406	using	use	VBG	B-VP
O	1407	1411	high	high	JJ	B-NP
O	1411	1412	-	-	HYPH	I-NP
O	1412	1422	resolution	resolution	NN	I-NP
O	1423	1433	ultrasound	ultrasound	NN	I-NP
O	1434	1442	enhanced	enhance	VBD	B-VP
O	1443	1447	with	with	IN	B-PP
O	1448	1456	contrast	contrast	NN	B-NP
O	1457	1469	microbubbles	microbubble	NNS	I-NP
O	1470	1478	revealed	reveal	VBD	B-VP
O	1479	1483	that	that	IN	B-SBAR
O	1484	1487	the	the	DT	B-NP
O	1488	1495	effects	effect	NNS	I-NP
O	1496	1498	of	of	IN	B-PP
O	1499	1503	LeTx	LeTx	NN	B-NP
O	1504	1506	on	on	IN	B-PP
B-Cancer	1507	1512	tumor	tumor	NN	B-NP
O	1513	1522	perfusion	perfusion	NN	I-NP
O	1523	1527	were	be	VBD	B-VP
O	1528	1538	remarkably	remarkably	RB	B-ADJP
O	1539	1544	rapid	rapid	JJ	I-ADJP
O	1545	1546	(	(	(	O
O	1547	1551	less	less	JJR	B-NP
O	1552	1556	than	than	IN	I-NP
O	1557	1559	24	24	CD	I-NP
O	1560	1561	h	h	NN	I-NP
O	1561	1562	)	)	)	O
O	1563	1566	and	and	CC	O
O	1567	1575	resulted	result	VBD	B-VP
O	1576	1578	in	in	IN	B-PP
O	1579	1580	a	a	DT	B-NP
O	1581	1587	marked	marked	JJ	I-NP
O	1588	1597	reduction	reduction	NN	I-NP
O	1598	1600	of	of	IN	B-PP
O	1601	1610	perfusion	perfusion	NN	B-NP
O	1611	1617	within	within	IN	B-PP
O	1618	1621	the	the	DT	B-NP
B-Cancer	1622	1627	tumor	tumor	NN	I-NP
O	1628	1631	but	but	CC	B-PP
O	1632	1635	not	not	RB	B-PP
O	1636	1638	in	in	IN	I-PP
B-Tissue	1639	1647	nontumor	nontumor	JJ	B-NP
I-Tissue	1648	1655	tissues	tissue	NNS	I-NP
O	1655	1656	.	.	.	O

O	1657	1662	These	These	DT	B-NP
O	1663	1670	results	result	NNS	I-NP
O	1671	1674	are	be	VBP	B-VP
O	1675	1685	consistent	consistent	JJ	B-ADJP
O	1686	1690	with	with	IN	B-PP
O	1691	1694	our	our	PRP$	B-NP
O	1695	1702	initial	initial	JJ	I-NP
O	1703	1713	hypothesis	hypothesis	NN	I-NP
O	1714	1717	and	and	CC	O
O	1718	1722	lead	lead	VBP	B-VP
O	1723	1725	us	us	PRP	B-NP
O	1726	1728	to	to	TO	B-VP
O	1729	1736	propose	propose	VB	I-VP
O	1737	1741	that	that	IN	B-SBAR
O	1742	1745	MKK	MKK	NN	B-NP
O	1746	1756	inhibition	inhibition	NN	I-NP
O	1757	1759	by	by	IN	B-PP
O	1760	1764	LeTx	LeTx	NN	B-NP
O	1765	1767	is	be	VBZ	B-VP
O	1768	1769	a	a	DT	B-NP
O	1770	1777	broadly	broadly	RB	I-NP
O	1778	1787	effective	effective	JJ	I-NP
O	1788	1796	strategy	strategy	NN	I-NP
O	1797	1800	for	for	IN	B-PP
O	1801	1810	targeting	target	VBG	B-VP
O	1811	1829	neovascularization	neovascularization	NN	B-NP
O	1830	1832	in	in	IN	B-PP
B-Cancer	1833	1846	fibrosarcomas	fibrosarcoma	NNS	B-NP
O	1847	1850	and	and	CC	O
O	1851	1856	other	other	JJ	B-NP
O	1857	1864	similar	similar	JJ	I-NP
B-Cancer	1865	1878	proliferative	proliferative	JJ	I-NP
I-Cancer	1879	1886	lesions	lesion	NNS	I-NP
O	1886	1887	.	.	.	O

